Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05796765 · ClinicalTrials.gov registry record · Phase 2
Phase 2B Micronized DHACM vs. Saline in the Treatment of Knee Osteoarthritis
A Phase 2 study, sponsored by MiMedx Group.
- Terminated
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
NCT05796765 is a Phase 2 study that was terminated before completion, run by MiMedx Group. The registered enrollment target is 43 participants.
The verdict
NCT05796765, a Phase 2 study, was terminated before completion, sponsored by MiMedx Group.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and efficacy of the 40 mg and 100 mg doses of allogeneic micronized dehydrated human amnion/chorion membrane (micronized DHACM) injectable compared to 0.9% sodium chloride injection, placebo control for the treatment of knee osteoarthritis
Interventions
- DRUG Saline
- BIOLOGICAL Micronized DHACM 40 mg
- BIOLOGICAL Micronized DHACM 100 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2023-03-24 |
| Est. Completion | 2023-12-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05796765
The ClinicalTrials.gov registry entry for NCT05796765 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MiMedx Group, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Saline is the first listed.
NCT05796765 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05796765 about?
NCT05796765 is a clinical study titled "Phase 2B Micronized DHACM vs. Saline in the Treatment of Knee Osteoarthritis". The purpose of this study is to determine the safety and efficacy of the 40 mg and 100 mg doses of allogeneic micronized dehydrated human amnion/chorion membrane (micronized DHACM) injectable compared to 0.9% sodium chloride injection, placebo control for the treatment of knee osteoarthritis
What is the current status of trial NCT05796765?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2023-03-24. Estimated completion is 2023-12-15.
What interventions are being tested in trial NCT05796765?
The interventions under investigation include: Saline (DRUG), Micronized DHACM 40 mg (BIOLOGICAL), Micronized DHACM 100 mg (BIOLOGICAL).
Who is sponsoring clinical trial NCT05796765?
This trial is sponsored by MiMedx Group, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.